Parteck^® PLX 188 (Poloxamer 188)

(C₃H₆O · C₂H₄O)_x

MFCD00082049

With formulation challenges in mind, we have used particle engineering technologies to develop functional excipients specifically for solid oral dosage forms. The products in our Parteck^® portfolio feature unique particle properties tailored for excellent performance in tableting processes, for specific drug delivery technologies, or for solubility enhancement.
As part of our Emprove^® Program, our raw materials are offered with extensive documentation facilitating compliance of your pharma and biopharma product, full supply chain transparency and risk mitigation. Our SAFC^® portfolio of high-quality products for biopharmaceutical and pharmaceutical formulation and production withstands strict quality control procedures and is produced according to applicable cGMP guidelines.

Parteck^® PLX 188 excipient combines adequate lubrication at tolerable concentrations with the added benefit of dissolution enhancement. It features consistent performance, improved dissolution rate and reliable lubrication – all at the same time. As a result, Parteck^® PLX 188 excipient can therefore provide a simple solution to low bioavailability of DCS 2a compounds.

Emprove is a registered trademark of Merck KGaA, Darmstadt, Germany
PARTECK is a registered trademark of Merck KGaA, Darmstadt, Germany
SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany

500

synthetic

NF
Ph. Eur.

EMPROVE^® ESSENTIAL

>150 ℃

55 ℃

1050 kg/m³

2-25℃

1S/C3H6O.C2H4O/c1-3-2-4-3;1-2-3-1/h3H,2H2,1H3;1-2H2

RVGRUAULSDPKGF-UHFFFAOYSA-N

10 - Combustible liquids

WGK 1